Giredestrant Combination Delays Progression in Advanced Breast Cancer, with Greater Benefit in the ESR1-Mutated Population

For patients with advanced breast cancer who rely on endocrine therapy to control their disease, the development of tumor resistance often means having to find another treatment option. Newly released results from the phase 3 evERA trial show that oral giredestrant combined with everolimus can delay disease progression longer than standard endocrine therapy combined with everolimus, providing important additional evidence for disease control after existing treatment has failed.

The full results of this study have been published in The New England Journal of Medicine. According to information from Dana-Farber Cancer Institute and CancerNetwork, the trial enrolled 373 patients with estrogen receptor–positive (ER-positive), HER2-negative locally advanced or metastatic breast cancer, all of whom had experienced disease progression or recurrence after treatment with a CDK4/6 inhibitor and endocrine therapy. Patients were randomly assigned to receive one of two treatments. The median follow-up was 18.6 months, and approximately 55% of tumors carried ESR1 mutations.

Among all participants, median progression-free survival was 8.8 months in the giredestrant group and 5.5 months in the control group; the hazard ratio for disease progression or death was 0.56 (95% confidence interval, 0.44 to 0.71; P<0.001). Progression-free survival measures the time from randomization to disease progression or death. This difference therefore represents more sustained disease control and cannot be directly interpreted as patients living 3.3 months longer.

The difference was greater in the ESR1-mutated population: median progression-free survival in the two groups was 10.0 and 5.5 months, respectively, with a hazard ratio of 0.38 (95% confidence interval, 0.27 to 0.54; P<0.001). ESR1 is the gene that encodes the estrogen receptor, and these mutations are associated with resistance to endocrine therapy. Giredestrant is a selective estrogen receptor degrader that weakens tumor growth signals by promoting receptor breakdown; everolimus, its combination partner, acts on the mTOR pathway.

Alongside improvements in disease control, the treatment burden must also be considered. CancerNetwork reported that the most common adverse events in both groups included stomatitis, diarrhea, and anemia, with stomatitis occurring in nearly half of patients in each group. Roche stated that there were no unexpected safety signals, no photopsia was observed, and the incidence of bradycardia was low; these findings still do not mean that the treatment has no side effects.

The study used an open-label design, meaning patients and physicians knew which treatment was being used, and the primary endpoint was assessed by investigators. CancerNetwork noted that progression-free survival results from a blinded independent central review were similar. The trial was funded by Roche. Overall survival data are currently immature. Although preliminary estimates favor the giredestrant group, they remain insufficient to confirm that the treatment can extend life, and further follow-up will be key to assessing its clinical value.

This publication provides more complete journal data on the preliminary results previously presented at ESMO 2025. According to Roche's announcement, the U.S. FDA has accepted the marketing application for giredestrant combined with everolimus for ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation, with a target decision date of December 18, 2026. Neither acceptance of the application nor trial success constitutes approval; whether this combination can enter clinical use still depends on regulators' overall review of its efficacy and safety.